Literature DB >> 25358665

Yttrium-90 radioembolization is a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases: further evidence in support of a new treatment paradigm.

Ryan Hickey1, Robert Lewandowski, Riad Salem.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25358665     DOI: 10.1245/s10434-014-4165-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  5 in total

1.  Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.

Authors:  Martin Law; K K Wong; W K Tso; Victor Lee; M Y Luk; C C Tong; Ferdinand Chu
Journal:  Br J Radiol       Date:  2016-12-20       Impact factor: 3.039

2.  Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy.

Authors:  Rita Golfieri; Cristina Mosconi; Emanuela Giampalma; Alberta Cappelli; Maria Cristina Galaverni; Cinzia Pettinato; Matteo Renzulli; Fabio Monari; Renzo Mazzarotto; Carmine Pinto; Bruna Angelelli
Journal:  Radiol Med       Date:  2015-02-13       Impact factor: 3.469

Review 3.  Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?

Authors:  Bippan Singh Sangha; Halla Nimeiri; Ryan Hickey; Riad Salem; Robert J Lewandowski
Journal:  Curr Treat Options Oncol       Date:  2016-06

Review 4.  Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.

Authors:  John R Eisenbrey; Helena Gabriel; Esika Savsani; Andrej Lyshchik
Journal:  Abdom Radiol (NY)       Date:  2021-04-07

Review 5.  Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist.

Authors:  Javier Torres-Jiménez; Jorge Esteban-Villarrubia; Reyes Ferreiro-Monteagudo; Alfredo Carrato
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.